Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

In August, EPKINLY was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all remaining provinces, including Nova Scotia, British ...

However, on October 11, the CME FedWatch tool showed that 89.5% of the market now expects a 25 bps rate cut and the rest ...

Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...

In July, Genmab (NASDAQ:GMAB) announced that the U.S. FDA has approved EPKINLY (epcoritamab-bysp) for treating adults with relapsed or refractory follicular lymphoma (FL) after two or more lines ...

Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...